Patient survivals on continuous ambulatory peritoneal dialysis (CAPD) seem similar to survivals on hemodialysis (HD) in comparable populations. Technique survivals are improving on CAPD as peritonitis rates fall with the use of disconnect devices. Advances in catheter design and catheter care appear to be improving catheter survivals. The peritoneal membrane appears usable for many years provided that recurring peritonitis can be avoided. Mesothelial cell transplantation, low calcium solutions, and urea kinetic modeling are important new areas of interest with potentials to improve the therapy. Evidence continues to mount that residual renal function is better preserved in CAPD than in HD.